Partner

Abcam (Abcam PLC)

Website

www.abcam.com

Short Name

Abcam

Brief description of institution/company

Abcam is a global biotechnology company specialising in reagents and kits for research. We have over 700 employees globally working research, production and administration. Our focus is on enabling scientists to discover more, with our high-quality protein research tools, expert technical support, fast global delivery, and up-to-date and honest data.

Scientists

Dr. Gary P. Dillon

Department

Technology and R&D

Role in Consortium

Training and Secondments

Brief CV

since 2010Joined Abcam Cambridge as a Senior scientist, Head of R&D from 2013.
2009 - 2010Post Doctoral researcher at the Wellcome Trust Sanger insitute.
2006 - 2009Post Doctoral researcher at University of York, UK
2002 - 2006PhD thesis Parasitology, University of York, UK
1998 - 2002Undergraduate reading Biochemistry, University of York, UK

Keywords Research Activities

  • Antibody generation and engineering
  • Display techniques for in vitro selection
  • Alternative scaffolds
  • Next generation sequencing/bioinformatics
  • Imaging techniques

Key publications or research/innovation products

  1. Otto T.D.; Dillon G.P.; Degrave W.S.; Berriman M. (2010) RATT: Rapid Annotation Transfer Tool. Nucleic Acids Res. 1;39(9):e57
  2. Berriman, M.; Haas, B.; LoVerde, P.T.; Wilson, R.A.; Dillon, G.P.; Cerqueira, G.C. et al. (2009) The Genome of the blood fluke Schistosoma mansoni. Nature. 460(7253):352-8.
  3. Wilson, R.A.; Langermans, J.A.M.; Van Dam, G.J.; Vervenne, R.A.; Hall, S.L.; Borges, W.C.; Dillon, G.P.; Thomas, A.W.; Coulson, P.S. (2008) Elimination of Schistosoma mansoni adult worms by rhesus macaques: basis for a therapeutic vaccine? PLoS Negl Trop Dis. 2(9):e290.
  4. Dillon, G.P.; Illes, J.C.; Isaacs, H.V.; Wilson, R.A. (2007) Patterns of gene expression in schistosomes: localization by whole mount in situ hybridization. Parasitology. 134(11):1589-97.
  5. Verjovski-Almeida, S.; DeMarco, R.; Martins, E.A.; Guimaraes, P.E.; Ojopi, E.P.; Paquola, A.C.; Piazza, J.P.; Nishiyama, M.Y.,Jr.; Kitajima, J.P.; Adamson, R.E.; Ashton, P.D.; Bonaldo, M.F.; Coulson, P.S.; Dillon, G.P.; et al. (2003) Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni. Nature Genetics. 35(2):148-157

AFFiRiS AG
Vienna, Austria

Website

www.affiris.com

Short Name

Brief description of institution/company

AFFiRiS develops synthetic vaccines against chronic diseases with unmet medical needs. The antigens of these vaccines are short peptides which function as B-cell epitopes. The aim of an AFFITOPE vaccination is to induce antibody immune responses which will address each target structure with the relevant appropriate specificity. The T-cell help required is provided by a carrier protein such as KLH covalently linked to the peptides. The basis for these developments is the proprietary AFFITOME® technology.

Scientists

Dr. Günther Staffler

Function

Chief Technical Officer

Phone

Email

Role in Consortium

CRISPR Tx (CRISPR Therapeutics Ltd)

Website

www.crisprtx.com

Short Name

CRISPR Tx

Brief description of institution/company

CRISPR Therapeutics is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough genome-editing technology, into transformative medicines for serious human diseases. We are uniquely positioned to translate CRISPR-Cas9 technology into human therapeutics, thanks to our multi-disciplinary team of world-renowned academics, clinicians and drug developers.

CRISPR Therapeutics' vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK and Cambridge, Massachusetts.

Scientists

Dr. Rodger Novak

Department

CEO, Crispr Therapeutics Ltd.

Phone

Email

rodger.novak@crisprtx.com

Role in Consortium

Training

Brief CV

2013 - PresentFounder and CEO CRISPR Therapeutics
2011 - 2013Vice President, Head TSU Infectious Diseases, Sanofi Global R&D
2006 - 2011Chief Operating Officer and Founder of Nabriva Therapeutics AG
2003 - 2006Deputy Head - Antibiotic Research Institute (ABRI), Sandoz Austria
2001University Professor (Microbiology & Genetics), Vienna Biocenter, University of Vienna, Austria

Selected Awards

2000The Merck ICAAC Young Investigator Award of the American Society for Microbiology – price of USD 10.000
1998ICAAC Program Committee Award of the American Society for Microbiology in the area of "Resistance: Mechanism and Consequences" – price of USD 5.000
1996Award for outstanding presentation in the section: Inflammatory Brain Diseases. International Congress of Neurology, Göttingen, Germany

Prof. Dr. Emmanuelle Charpentier

Department

Regulation in Infection Biology / MPI for Infection Biology

Phone

+49 30 28460-410

Email

office-charpentier@mpiib-berlin.mpg.de

Role in Consortium

Training

Brief CV

Since 2014Guest Prof., Lab Head; MIMS, UCMR, Dept. Mol. Biol., Umeå Univ., Umeå, Sweden
Since 2013Full Prof., AvH Prof.; MHH. Dept. (REGI) Head, HZI, Braunschweig, Germany
2013Docent (Medical Microbiology); Faculty of Medicine, Umeå Univ., Umeå, Sweden
2009 - 2013Assoc. Prof., Lab Head; The Laboratory for Mol. Infection Medicine Sweden, EMBL Nordic Node (MIMS), UCMR, Dept. Mol. Biol., Umeå Univ., Umeå, Sweden
2006 - 2009Assoc. Prof., Lab Head; Max F. Perutz Laboratories, Univ. of Vienna, Vienna, Austria
2006Priv.-Doz., Professorial Dissertation (Microbiology); Univ. of Vienna, Vienna, Austria
2004 - 2006Assist. Prof., Lab Head; Dept. Microbiol. & Immuno., Univ. of Vienna, Vienna, Austria
2002 - 2004Guest Prof., Lab Head; Inst. Microbiol. & Genet., Univ. of Vienna, Vienna, Austria
1999 - 2002Research Assoc.; Skirball Inst. of Biomol. Medicine, New York, USA
1999Research Assoc.; St. Jude Children's Research Hospital, Memphis, TN, USA
1997 - 1999Research Assist.; New York Univ. Medical Center, New York, NY, USA
1996 - 1997Post-doctoral Assoc.; The Rockefeller Univ., New York, NY, USA
1995 - 1996Post-doctoral Assist.; Pasteur Inst., Paris, France
1995Ph.D. Degree (Microbiology); Univ. P. & M. Curie, Pasteur Inst., Paris, France
1992Master Degree (Microbiology); Univ. P. & M. Curie, Pasteur Inst., Paris, France

Selected Awards

2015Umeå University EC Jubilee Award
2015Gruber Prize in Genetics
2015Hansen Family Award
2015Princess of Asturias Award for Technical and Scientific Research
2015Elected Fellow of the American Academy of Microbiology
2015Louis Jeantet Prize for Medicine
2015 Ernst Jung Prize for Medicine
2015Breakthrough Prize in Life Science
2014Grand Prix Jean-Pierre Lecocq
2014Dr Paul Janssen Award for Biomedical Research
2014Elected EMBO Member
2014Göran Gustafsson Prize
2013Alexander von Humboldt (AvH) Professorship

Keywords Research Activities

  • Regulator mechanisms in processes of infection and immunity with a focus on Gram-positive bacterial pathogens, especially, we are interested in
    • CRISPR-Cas: RNA-mediated interference in immunity
    • Regulatory small RNAs
    • Regulatory protein quality control
    • Regulation by RNAs and proteins in innate immuntiy

Key publications or research/innovation products

  1. Doudna JA and Charpentier E. 2014. The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096.
  2. Jinek M, Jiang F, Taylor DW, Stenberg SH, Kaya E, Ma E, Anders C, Hauer M, Zhou K, Lin S, Kaplan M, Iavarone AT, Charpentier E, Nogales E and Doudna JA. 2014. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science 343(6176):1247997.
  3. Fonfara I, Le Rhun A, Chylinski K, Makarova KS, Lécrivain AL, Bzdrenga J, Koonin EV and Charpentier E. 2014. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. Nucleic Acids Res. 42(4):2577-2590.
  4. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA and Charpentier E. 2012. A programmable dual-RNA guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816-821.
  5. Deltcheva E, Chylinski K, Sharma C, Gonzales K, Chao Y, Pirzada ZA, Eckert M, Vogel J and Charpentier E. 2011. CRISPR RNA maturation by trans-encoded small RNA and host factor RNAse III. Nature 471(7340):602-607.

Eagle (Eagle Genomics Ltd)

Website

www.eaglegenomics.com

Short Name

EAG

Brief description of institution/company

Eagle provides world-class bioinformatics services to commercial organisations supporting the management, analysis and exploitation of genomics and Next Generation Sequencing (NGS) related data. Eagle has worked with over 30 international blue-chip customers across the pharmaceutical, biotech, healthcare, crop science, biofuels, animal health, food and personal hygiene sectors. Eagle successfully addresses scientific information management challenges to life science R&D with a combination of cloud-based computing capabilities and bioinformatics expertise. -- from whole genome browsing configuration (eaglensembl), to genomic analysis workflow management (eaglehive), and an innovative platform for the cataloguing of large-scale datasets and metadata across an entire organisation (eaglecore). Eagle Genomic delivers on expert capabilities for accelerating R&D discovery.

Scientists

Dr. William Spooner

Department

Research and Development

Phone

+44 7779 663045

Email

william.spooner@eaglegenomics.com

Role in Consortium

Training and Secondments

Brief CV

since 2008Founder and Chief Science Officer, Eagle Genomics Ltd., Cambridge, UK
2005 - 2012Consultant, Cold Spring Harbor Laboratory, USA
2004 - 2009Visiting Scientist, European Bioinformatics Institute, Hinxton, UK
2001 - 2004Bioinformatics Developer, Welcome Trust Sanger Institute, Hinxton, UK
1998 - 2001Software Developer, Zeus Technology Ltd, Cambridge, UK

Selected Awards

2000PhD Earth System Modelling, University of Southampton, UK.
1995BSc Marine Environmental Chemistry, University of Southampton, UK.

Keywords Research Activities

  • Genome informatics
  • High throughput data processing
  • Information management
  • Metadata management
  • Cloud computing

Key publications or research/innovation products

EMBL - EBI
(European Molecular Biology Laboratory -
European Bioinformatics Institute)
Camebridge, UK

Website

www.ebi.ac.uk

Short Name

EMBL-EBI

Brief description of institution/company

EMBL-EBI research: About 20% of EMBL-EBI is devoted to collaborative, investigator-led research using computational approaches to unravel the secrets of life. Our research is carried out both in groups devoted solely to research and in some of the larger service teams that have associated research activities. All researchers have computational approaches as their major focus, but most also collaborate closely with experimentalists and even generate experimental data themselves.

Scientists

Dr. Cath Brooksbank

Department

Head of Training

Phone

+44 1223 492525

Email

cath@ebi.ac.uk

Website of Lab

www.ebi.ac.uk/training/

Role in Consortium

Training

Brief CV

2012 - present:Head of Training, EMBL-EBI
2006 - 2012:Head of Outreach and Training, EMBL-EBI
2002 - 2006:Scientific Outreach Officer, EMBL-EBI
1993 - 2002:Locum Subeditor, Associate Editor, Managing Editor and Editor of various journals (Nature Reviews Molecular Cell Biology, Nature Reviews Cancer, Elsevier Trends Journals, Molecular Medicine Today)
1989 - 1993:PhD at University of Cambridge (UK)
1986 - 1989:Medicine Training at University of Oxford (UK)

Key publications or research/innovation products

  1. Welch, L. et al. (2014) Bioinformatics curriculum guidelines: toward a definition of core competencies. PloS Comput Biol. 10, e1003496
  2. Brooksbank, C. et al. (2014) The European Bioinformatics Institute's data resources 2014. Nucleic Acids Res. 42, 18–25
  3. Hardman, M. et al. (2013) LifeTrain: towards a European framework for continuing professional development in biomedical sciences Nature Rev. Drug Discov. 12, 407–408
  4. Klech, H. et al. (2012) European initiative towards quality standards in education and training for discovery, development and use of medicines. Eur. J. Pharmaceut. Sci. 45, 515–520
  5. Wright, V. A. et al. (2010) Bioinformatics training: Selecting an appropriate learning content management system – an example from the European Bioinformatics Institute. Brief. Bioinformat. 11, 552–562

Genomatix Software GmbH
Munich, Germany

Website

www.genomatix.de

Short Name

Genomatix

Brief description of institution/company

Genomatix is one of the world's leading suppliers of technologies to analyze and interpret genomic data. With a focus on microarray and NGS data analysis, our hardware and software solutions also help to answer the typical questions posed by systems biology. Our approach: combine multiple lines of evidence to perform an integrated meta-analysis.

Scientists

Dr. Christian Zinser

Department

Consulting

Phone

+49 89 599766 0

Email

zinser@genomatix.de

Role in Consortium

Training and Secondments

Brief CV

since 2010Head of Consulting, Genomatix Software GmbH, Munich, Germany
2008 - 2010Head of Training, Genomatix Software GmbH, Munich, Germany
2006 - 2007Application Scientist, Genomatix Software GmbH, Munich, Germany
2005 - 2006Application Developer, Pixel GmbH, Gr‰felfing, Germany
2001 - 2005Database Administrator, Ingenium Pharmaceuticals AG, Martinsried, Germany
2000 - 2001Database Administrator, Staticon International GmbH, Martinsried, Germany
1999 - 2000Training as Software Developer / Database Administrator, ptm Academy, Munich, Germany
1996 - 1998Post-Doc at Botanical Institute, Ludwig Maximilian University of Munich, Germany
1992 - 1996PhD thesis, Helmholtz Center Munich, Germany (formerly GSF National Research Center for Environment and Health)
1987 - 1991Undergraduate studies in Biology, Ludwig Maximilian University of Munich, Germany
1985 - 1987Undergraduate studies in Biology, University of Regensburg, Germany

Selected Awards

2012"Industriepreis 2012" in the biotech category at Hannover Messe
2012Finalists of Boston Children's Hospital's CLARITY challenge
2011Illumina's Data Excellence (iDEA) Challenge 2011 "Most creative visualization" in the commercial category

Key publications or research/innovation products

  1. Supper J, Gugenmus C, Wollnik J, Drueke T, Scherf M, Hahn A, Grote K, Bretschneider N, Klocke B, Zinser C, Cartharius K, Seifert M (2013) Detecting and visualizing gene fusions. Methods. 2013 Jan;59(1):S24-8
  2. Riedmaier I, Benes V, Blake J, Bretschneider N, Zinser C, Becker C, Meyer HH, Pfaffl MW (2012) RNA-Sequencing as Useful Screening Tool in the Combat against the Misuse of Anabolic Agents. Anal Chem. 2012 Aug 7;84(15):6863-8. Epub 2012 Jul 13
  3. Seitz V, Butzhammer P, Hirsch B, Hecht J, Gütgemann I, Ehlers A, Lenze D, Oker E, Sommerfeld A, von der Wall E, König C, Zinser C, Spang R, Hummel M (2011) Deep Sequencing of MYC DNA-Binding Sites in Burkitt Lymphoma. PLoS One. 2011;6(11):e26837. Epub 2011 Nov 10
  4. Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, Ravo M, Tarallo R, Luo S, Schroth GP, Seifert M, Zinser C, Chiusano ML, Traini A, De Bortoli M, Weisz A (2010) Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol. 2010 May;176, 2113-30

Novimmune SA
Geneva, Switzerland

Website

www.novimmune.com

Short Name

NI

Brief description of institution/company

Novimmune SA (NI) is a privately held drug discovery and development company located in Geneva, Switzerland focusing on developing therapeutic antibodies for inflammatory diseases, autoimmune disorders and cancer. Novimmune's has created and advanced several products into clinical trials in patients. The staff of 100 people is divided across the departments of Research, Translational Sciences, Bioprocessing and Clinical Science/Safety/Operations.

Scientists

Marie H. Kosco-Vilbois, PhD

Department

Novimmune SA

Phone

+41 22 839 7141

Email

mkosco-vilbois@novimmune.com

Role in Consortium

Training

Brief CV

Since 2005Chief Scientific Officer, NovImmune S.A., Geneva Switzerland
2002 - 2005Director of Research, NovImmune S.A., Geneva Switzerland
1998 - 2002Head of Immunology, Serono Research Institute, Geneva Switzerland
1994 - 1998Head of Immunology Glaxo Wellcome Research Institute, Geneva
1989 - 1994Scientific Member, Basel Institute for Immunology, Basel, Switzerland.
1985 - 1989Postdoctoral Fellow, Department of Microbiology & Immunology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA USA
1980 - 1985Doctor of Philosophy (Ph.D.), Department of Anatomy, Division of Immunology,
Medical College of Virginia, VCU, Richmond, VA USA

Keywords Research Activities

  • Germinal center reactions
  • Autoimmune diseases
  • TLR4 biology
  • Chemokines
  • Cancer immunology

Key publications or research/innovation products

  1. Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurendon A, Gueneau F, Ravn U, Depoisier JF, Moine V, Raimondi S, Malinge P, Di Grazia L, Rousseau F, Poitevin Y, Calloud S, Cayatte PA, Alcoz M, Pontini G, Fagète S, Broyer L, Corbier M, Schrag D, Didelot G, Bosson N, Costes N, Cons L, Buatois V, Johnson Z, Ferlin W, Masternak K, Kosco-Vilbois M. (2015) Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun. Feb 12;6:6113.
  2. Giovannoni L, Muller YD, Lacotte S, Parnaud G, Borot S, Meier RP, Lavallard V, Bédat B, Toso C, Daubeuf B, Elson G, Shang L, Morel P, Kosco-Vilbois M, Bosco D, Berney T. (2015) Enhancement of islet engraftment and achievement of long-term islet allograft survival by Toll-like receptor 4 blockade. Transplantation. 2015 Jan;99(1):29-35.
  3. Shang L, Daubeuf B, Triantafilou M, Olden R, Dépis F, Raby AC, Herren S, Dos Santos A, Malinge P, Dunn-Siegrist I, Benmkaddem S, Geinoz A, Magistrelli G, Rousseau F, Buatois V, Salgado-Pires S, Reith W, Monteiro R, Pugin J, Leger O, Ferlin W, Kosco-Vilbois M, Triantafilou K, Elson G.(2014) Selective antibody intervention of Toll like Receptor 4 activation through Fc gamma receptor tethering. J Biol Chem. 289:15309-18.
  4. Zhang Y, Meyer-Hermann M, George LA, Figge MT, Khan M, Goodall M, Young SP, Reynolds A, Falciani F, Waisman A, Notley CA, Ehrenstein MR, Kosco-Vilbois M, Toellner KM. (2013) Germinal center B cells govern their own fate via antibody feedback. J Exp Med., 210(3):457-64.
  5. Garin A, Meyer-Hermann M, Contie M, Figge MT, Buatois V, Gunzer M, Toellner KM, Elson G, Kosco-Vilbois MH. (2010) Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation. Immunity. 33:84-95.